Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
DeNardo DG, Galkin A, Dupont J, et al. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. J Immunother Cancer 2021;9:e003005. doi: 10.1136/jitc-2021-003005.
This article has been corrected since it was first published. The Y axis of Figure 3B has been updated to ‘CD11b IHC prevalence (% positive)’.